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GENERAL INTRODUCTION 
Canine adenovirus type 1 (CAV-1) was isolated by Cabasso et al. in 
1954 from a dog with acute hepatitis and shown to be identical to the 
infectious canine hepatitis (ICH) virus described by Rubarth in 1947 
(7, 24). In 1962, Ditchfield et al. isolated a different canine adeno­
virus from throat swabs of a dog with laryngotracheitis. This strain of 
canine adenovirus type 2 (CAV-2) was called Toronto A26/61 (12). Several 
strains of CAV-1 and CAV-2 have since been described, and differentiation 
between the two has been based on studies of morphology (18), cyto-
pathology in cultured cells (1, 29), serology (4, 11, 26), and patho­
genicity (2, 4, 27). 
Morphology, serology, and in vitro cytopathology studies have left 
ambiguities as to the distinctness of the two viruses. The greatest 
difference shown between type 1 and 2 has been in the pathogenicity of 
the two viruses. With CAV-1, the classical disease is infectious 
hepatitis, but infections can range from inapparent to fulminating fatal 
disease, including respiratory syndromes similar to those associated with 
CAV-2 infection. The virus has an affinity for hepatic parenchymal, 
Kupffer's, and endothelial cells. Virus has been isolated readily from 
the liver, kidneys, and lymphoid organs. The viremia resulting from 
infection with CAV-1 also leads to a phenomenon called "blue eye", a type 
III hypersensitivity reaction in which immune complex formation resulting 
from the release of virus brings about corneal endothelial damage and 
edema. The blue eye syndrome is attributable to both natural infection 
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with CAV-1 and to vaccination with modified live type 1 virus (10). The 
pathogenesis of CAV-2, on the other hand, is largely confined to the 
respiratory system, and is associated with a condition often referred to 
as "kennel cough". The type 2 virus does not readily cause viremia, and 
blue eye is not observed. Because of the potential problem of blue eye 
associated with vaccination with CAV-1, many veterinary biologies firms 
now market CAV-2 vaccines since a vaccine produced from either virus will 
cross-immunize against the heterologous virus (3, 8, 9, 13). 
The CAVs currently used for vaccine production in the United States 
include the Cornell-1 and Lederle 255 strains of CAV-1 and the 
Toronto A26/61 (Ditchfield) and Manhattan strains of CAV-2. Until now, 
identification and classification of the master seed virus (the virus 
from which subsequent vaccine is produced) have had to come from studies 
on pathogenicity, morphology, cytopathology, and serology. Although 
taken collectively, these data may provide an accurate evaluation of the 
identity of a CAV type, there is currently no individual test, especially 
in vitro, that can do this. Additionally, although differences have been 
shown between CAV-1 and CAV-2 in pathogenicity (12, 27), morphology 
(CAV-1 fiber is 25-27 nm as compared with CAV-2 fiber which is 35-37 nm) 
(18), and antigenicity (11, 26,), these two viruses are still not 
recognized, by definition, as two distinct adenovirus species (types) 
(19, 34). Quantitative cross-neutralization studies with CAV-1 and CAV-2 
have not shown immunologic distinctiveness by demonstrating either no 
cross-reaction or homologous-to-heterologous titer ratios of >16 in both 
directions. 
The purpose of this investigation was to develop a method(s) that 
would differentiate, in vitro, CAV-1 from CAV-2. Additionally, it would 
be useful if such a method or methods could identify strains within a 
given type so that vaccine and field strains could be discriminated. 
Inherent to the success of this enterprise was the proof that CAV-1 and 
CAV-2 are immunologically distinct species of CAV. The experiments that 
were performed to accomplish these goals are described in the two papers 
entitled, "Restriction enzyme analysis of canine adenoviruses 1 and 2: 
differentiation of strains used for vaccine production in the United 
States," and "Characterization of the canine adenoviruses 1 and 2 by 
immunofluorescence, virus neutralization, and immunoprecipitation using 
monoclonal antibodies," which comprise the body of this dissertation. 
vii 
DISSERTATION FORMAT 
This dissertation is presented as an alternate format which includes 
two manuscripts to be submitted to scientific journals for publication. 
Both will be submitted to the Journal of Virology. The manuscripts are 
presented in the format required for the dissertation. References are 
cited at the end of each manuscript and are in compliance with the 
journal. The manuscripts are preceded by a general introduction. A 
summary and discussion section follows the last manuscript. Literature 
cited in those sections is listed after the summary and discussion. 
The Ph.D. candidate, Cecelia Anne Whetstone, was the principal 
investigator for each of the investigations and is the sole author for 
both manuscripts. Dr. P. M. Gough served as major professor. 
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PART I: RESTRICTION ENZYME ANALYSIS OF CANINE ADENOVIRUSES 1 AND 2; 
DIFFERENTIATION OF STRAINS USED FOR VACCINE PRODUCTION IN THE 
UNITED STATES 
This manuscript has been submitted for publication to the Journal of 
Virology. 
Four strains of canine adenovirus type 1 [CAV-1 (Utrecht, Lederle 
255, Cornell-1-66, Cornell-1-PK)] and two strains of canine adenovirus 
type 2 [CAV-2 (Manhattan, Toronto A26/61, also referred to as Ditch-
field)] were examined by restriction enzyme analysis. Each of these, 
except Utrecht, is used for vaccine production in the United States. The 
two types of adenoviruses could be readily differentiated on the basis of 
restriction patterns obtained using either enzymes Bam HI, Eco RI, Kpn I 
or Bgl II. Differences between strains within the same virus type, 
however, were not as conspicuous. Among the CAV-1 strains, only 
Cornell-l-PK showed restriction patterns that were distinct from the 
other strains. Between the CAV-2 strains, small pattern dissimilarities 
could be detected only with the use of the restriction enzymes Bam HI and 
Eco Rl. 
Two types of canine adenoviruses (CAV) have been described. In 
1954, Cabasso et al. isolated canine adenovirus type 1 (CAV-1) from a dog 
with acute hepatitis and showed this virus to be identical to the one 
designated by Rubarth (1947) as infectious canine hepatitis virus 
(9, 31). Subsequently, Ditchfield et al. (1962) isolated canine adeno­
virus type 2 (CAV-2) from throat swabs of a dog with laryngo-
tracheitis (17). Although several isolates of CAV have since been 
described, all have been identified by serology, pathology, clinical 
signs, and virus morphology as either CAV-1 or CAV-2 (3, 6, 9, 15, 16, 
17, 35, 37, 38, 39, 44). Although differences between the two types 
occur in morphology, pathogenicity, and antigenicity (1, 3, 23, 37, 38), 
almost all mammalian adenoviruses share group-specific determinants 
located on the major capsid protein, hexon (10). Because of the shared 
group-specific determinants, serologic responses in animals exposed to 
one type of CAV are cross-reactive with the other type (3, 37, 38). 
Moreover, immunity to either pathogen can be induced by vaccination with 
homologous or heterologous CAV type (5, 11, 12, 13, 19, 40). Two strains 
of CAV-1 (Cornell-1 and Lederle 255) and two strains of CAV-2 
(Toronto A26/61 and Manhattan) are currently used for the production of 
vaccine in the United States. Conventional in vitro detection of these 
viruses with assays such as serum neutralization (SN) or hemagglutination 
inhibition are somewhat effective albeit indirect procedures for 
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distinguishing CAV-1 from CAV-2. None of the above techniques can be 
utilized for strain identification or differentiation. 
Discrimination between types and even subtypes of human adenoviruses 
has been accomplished with the use of restriction enzyme analysis of the 
viral genomes (2, 26, 32, 41, 42, 43). In this study, therefore, antici­
pating that this technique would also be useful in differentiating CAV 
types and possibly strains of the same type, I examined the prototype of 
CAV-1 and strains of each type that are used for vaccine production in 
the United States. By using the restriction endonucleases Bam HI, 
Eco RI, Kpn I, and Bgl II, I showed that it is possible to differentiate 
CAV-1 from CAV-2. Furthermore, in some instances, strains of the same 
type demonstrated similar but unique restriction profiles characteristic 
of that species. 
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MATERIALS AND METHODS 
Virus and Cells. Primary dog kidney and Madin and Darby canine 
kidney (MDCK) cells were maintained in Eagle's Minimum Essential Medium 
(MEM) with Earle's salts, 2 mM L-glutamine, 10% heat-inactivated bovine 
fetal serum (BPS), and gentamicln sulfate (50 mg/liter). The Utrecht and 
Lederle 255 strains of CAV-1 and the Toronto A26/61 (Ditchfield) strain 
of CAV-2 were obtained from the American Type Culture Collection, 
passaged one time in primary dog kidney cells, and stored at -60 C. The 
Cornell-1-66 and Cornell-l-PK strains of CAV-1 and the Manhattan strain 
of CAV-2 were a gift from Dr. L. E. Carmichael of Cornell University. As 
received, the Cornell-1-66 strain, a dog isolate (4), was at the third 
passage in primary canine kidney cells; the Cornell-l-PK strain was the 
16th passage of Cornell-1-66 in primary dog kidney cell cultures; and the 
Manhattan strain was the fifth dog kidney passage. All three of these 
viruses were passaged once in primary dog kidney cells and stored at 
-60 C. 
Virus Purification from Cell Culture. The MDCK cells were seeded at 
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a concentration of 2 x 10 cells/ml into 850 cm roller bottles contain­
ing MEM, supplemented as described. After 48 hours, 2 ml of each virus 
strain, diluted in MEM, were inoculated at a multiplicity of infection 
(MOI) of 0.2 to 0.02 onto two roller bottles and allowed to adsorb for 
one hour. Supplemented MEM was replaced and cells were incubated at 37 C 
until the CPE was 100% (about 4 to 5 days post-inoculation). Rollers 
were scraped to dislodge cells and the culture medium was clarified at 
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250 X g for 10 minutes. The supernatant fluid was then centrifuged 
through 40% sucrose (w/v in 0.2 M phosphate buffer, pH 7.5) at 
100,000 X g for 11/2 hours and the resulting viral pellet was 
resuspended in 2.0 ml of TE buffer (10 mM Tris, 1 mM EDTA, pH 7.6). A 
small volume (0.1 ml) was removed from each sample, inoculated onto MDCK 
cells, and examined by the FA technique for the presence of viable virus. 
Viral DNA Extraction. The 2.0 ml viral pellet suspension was 
treated with 20 jil sodium dodecyl sulfate [(SDS) 20%], 200 ul 
proteinase K (1 mg/ml), and incubated at 37 C for 1 to 2 hours until 
cleared. Extraction was performed using an equal volume of TE buffer-
saturated phenol (distilled) one time, 1/2 volumes each phenol and 
chloroform one time, and an equal volume of chloroform two times, taking 
care to save the interface until the last extraction. The DNA was then 
ethanol precipitated, resuspended in TE buffer, and stored either at 
-20 C or at 4 C until used. 
Restriction Enzyme Analysis. Restriction enzymes [Bethesda Research 
Laboratories, Inc. (BRL)] were stored, diluted, and used in running 
buffers as prescribed by the company. Human adenovirus 2 (Ad 2) DNA 
(from BRL) was used as a standard. Enzyme reactions were stopped with 
10 yl of a mixture of 0.02% bromphenol blue in 60% sucrose [w/v in 
Loening's buffer (36 mM Tris, 30 mM NaHgPO^, 1 mM EDTA, pH 7.7)]. 
Cleaved DNAs were electrophoresed in a horizontal chamber at a constant 
45 volts for 16 to 17 hours in a 0.8% gel (SeaKEM ME agarose) in 
Loening's buffer. The DNA was then stained with ethidium bromide 
(1 pg/ml), viewed with UV illumination of approximately 360 nm, and 
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photographed through a red-orange filter. Molecular weights were 
estimated graphically using Ad 2 as the molecular weight standard and 
plotting the logarithm of the fragment size against the mobility. 
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RESULTS 
Selection and Purification of Viruses. The virus strains examined 
and the rationale for selecting those strains are presented in Table 1. 
After virus titers were determined in MDCK cells, a low MOI was used to 
culture viruses for DNA extraction so that the frequency of adenovirus 
recombination and defective interference could be held to a minimum (18). 
Viral CPE was 100% by days 4 to 5 post-inoculation, at which time cells 
were harvested. Most of the cellular debris was removed by the 
clarification step eliminating contamination with host cell DNA during 
the extraction procedure. The presence of virus in each pellet was 
confirmed by the FA test on MDCK cells inoculated with a small volume of 
the resuspended pellet. 
Extraction of Viral DNA. Samples were treated with SDS and 
proteinase K to denature and degrade contaminating proteins. If one 
treatment with these agents did not yield a translucent sample, the 
treatment was repeated until the sample was clear. Because of the 
hydrophobic nature of the reaction of phenol with proteins, DNA can get 
trapped at the interface during extraction procedures. This problem is 
solved by re-extraction. Therefore, care was taken not to discard the 
interface until after the last extraction, which rendered noticeably 
better yields of DNA than when this precaution was not taken. 
Differentiation of Canine Adenoviruses by Restriction Enzyme 
Analysis. The restriction endonucleases Bam HI, Eco RI, Kpn I, and 
Bgl II were chosen for this study. Each of these enzymes recognizes a 
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different six base pair sequence in DNA, and all have been used to map 
the Ad 2 genome (28), the size marker used in this study. An 0.8% gel 
was used because it resolves fragments from approximately 300 to 
20,000 bp (33). Results of the restriction analysis are presented in 
Fig. 1. All enzymes cut Ad 2 DNA as predicted (28). With all enzymes 
used, CAV-1 and CAV-2 were easily differentiated. Among the CAV-1 
strains, there was no difference between the prototype virus, Utrecht, 
and the Lederle 255 and Cornell-1-66 strains. For the Cornell-l-PK 
strain, however, the restriction enzymes cut differently than for the 
other CAV-1 strains in all cases. Between the CAV-2 strains, there were 
no pattern differences using the enzymes Kpn I or Bgl II. With Bam HI, 
the Toronto A26/61 strain displayed an additional submolar band just 
below the 14 kb fragment, and with Eco RI, this same strain showed a 
small fragment just above the 21 kb fragment. Neither fragment was 
present in the restriction patterns for the Manhattan strain. Although 
the Eco RI pattern for Toronto A26/61 appeared to be a partial digest, 
the anomally was repeatable. Genome size for all strains of CAV-1 and 
CAV-2 tested were estimated from the gels at 20 to 21 x 10^ daltons, 
which agreed with the expected range for adenovirus (22). 
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DISCUSSION 
Differentiation of CAV-1 from CAV-2 has previously been based on 
studies of pathogenicity (3, 38), serology (6, 15, 37), cytopathology in 
cultured cells (1), and morphology (23). Studies of cytopathology in 
cultured cells have not readily differentiated CAV-1 from CAV-2, and 
morphological studies differentiated the two viral types only on the 
basis of fiber length, which is 25 to 27 nm for CAV-1 and 35 to 37 nm for 
CAV-2 (22). Among the CAVs, the use of serology for type distinction and 
strain identification has not been completely successful, because the 
cross-reactivity of the group specific hexon, the major antigenic protein 
for both viruses, masks any differences that might be present in other 
antigenic proteins. 
The greatest difference seen between type 1 and 2 has been shown in 
the pathogenicity of the two viruses. With CAV-1, the classical disease 
is infectious hepatitis, but infections can range from unapparent to 
fulminating fatal disease, including respiratory syndromes similar to 
those associated with CAV-2 infection. The virus has an affinity for 
hepatic parenchymal, Kupffer's, and endothelial cells. Virus has been 
isolated readily from the liver, kidneys, and lymphoid organs. The 
viremia resulting from infection with CAV-1 also leads to a phenomenon 
called "blue eye", a type III hypersensitivity reaction in which immune 
complex formation resulting from the release of virus brings about 
corneal endothelial damage and edema. The blue eye syndrome is attrib­
utable to both natural infection with CAV-1 and to vaccination with 
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modified live type 1 virus (14). The pathogenesis of CAV-2, on the other 
hand, is largely confined to the respiratory system, and is associated 
with a condition often referred to as "kennel cough". The type 2 virus 
does not readily cause viremia, and blue eye is not observed. Because of 
the potential problem of blue eye associated with vaccination with CAV-1, 
many veterinary biologies firms now market CAV-2 vaccines because a 
vaccine produced from either virus will cross-immunize against the 
heterologous virus (5, 11, 13, 19). Until now, identification and 
classification of the master seed virus (the virus from which subsequent 
vaccine is produced) have had to come from studies on pathogenicity, 
morphology, cytopathology, and serology. Restriction enzyme analysis 
provides a relatively simple, direct, objective, and definitive method 
for typing the master seed virus. 
An advantage of restriction enzyme analysis over older serologic 
classifications is sensitivity. Serologic methods rely on distinct 
antigenic determinants that induce antibodies. The gene products carry­
ing these antigenic determinants, however, represent only a few percent 
of the total viral genome, meaning that analysis of cross-reactions 
measured by serologic techniques gives information on only a few gene 
products, and is not necessarily representative of the relatedness of 
viral genomes. Sequence-specific endonucleases, such as the ones used in 
this study, are second only to nucleotide-sequence analysis in the 
detailed Information that can be gained on the homologies of related 
genomes. This fact has been proven repeatedly with the human adeno­
viruses (26, 41, 42, 43); human, bovine, porcine, and equine herpes-
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viruses (7, 8, 20, 21, 29, 34); parvoviruses (25); papovaviruses (36); 
and poxviruses (27). The restriction patterns generated with Bam HI, 
Eco RI, Kpn I, and Bgl II in this study all show that there are clearly 
two distinct genome types of canine adenovirus that can be readily 
differentiated from each other. Furthermore, strains of a given type 
that are truly different from the prototype can be detected. This is 
best illustrated with the Cornell-1 strains of CAV-1. The Cornell-1-66 
strain, a virulent isolate from a dog suffering infectious canine hepa­
titis (ICH), was lyophilized after three passages in primary dog kidney 
cells: its restriction patterns are identical to Utrecht, the prototype 
virus. The Cornell-l-PK strain is an attenuated version of the same 
virus after 16 passages in porcine kidney cells. Its restriction pat­
terns indicate that although it is still a type 1 CAV, it is now clearly 
a subtype. The Lederle 255 strain appears to be identical to Utrecht. 
There also seem to be small genetic differences between the CAV-2 strains 
detectable by restricting with Bam HI and Eco RI. 
Biologically, virus attenuation can be measured by reduced virulence 
in the host animal. Genomically, a difference between virulent and 
attenuated viruses has been shown with the porcine and equine herpes 
viruses in which the restriction enzyme patterns of vaccine strains are 
distinct from field isolates (21, 29, 34). Moreover, the stability of 
restriction patterns from a variety of viral isolates is well-documented 
(7, 8, 30, 36, 41). Since vaccines are limited to the number of times 
they can be passed, the chance of a pattern changing would be very 
slight. Attenuation of a virus, therefore, is not merely a product of 
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repeated passage of that virus, but rather a reflection of a genomic 
alteration that may be significant enough to be verified by restriction 
enzyme analysis. This study supports the concept that attenuated 
viruses, especially those that have been attenuated by passage in 
heterologous species cell cultures, may yield unique restriction patterns 
that provide a "fingerprint" of identification for that particular virus 
strain, a factor that becomes important in the differentiation of vaccine 
from field strains of virus. 
Finally, according to the latest report (1982) of the International 
Committee on the Taxonomy of Viruses, "a species (formerly type) of 
adenovirus is defined on the basis of its immunologic distinctiveness, as 
determined by quantitative neutralization with animal antisera. If 
neutralization shows a certain degree of cross-reaction between two 
viruses in either or both directions...distinctiveness of species is 
assumed if...(ii) substantial biophysical/biochemical differences of the 
DNAs exist" (24). As already discussed, the serologic cross-reactivity 
of CAV-1 and CAV-2 has led to ambiguity on the definitive typing of CAV-2 
as a distinct species from CAV-1. The data presented in this study 
indicate that there are substantial differences between these two viruses 
at the DNA level and that they should be recognized as separate CAV 
species. 
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TABLE 1. Virus strains used in the present study 
Virus Type Strain Reason for inclusion into study 
CAV-1 
CAV-1 
CAV-1 
CAV-1 
CAV-2 
CAV-2 
Utrecht 
Lederle 255 
Cornell-1-66 
Cornell-l-PK 
Toronto A26/61 
Manhattan 
Prototype 
Vaccine strain 
(Pre)-Vaccine strain 
Vaccine strain 
Vaccine strain 
Vaccine strain 
Fig. 1. Restriction enzyme analysis of CAV genomes (a) Ad2, 
(b) Utrecht (c) Lederle 255 (d) Cornell-1-66 
(e) Cornell-1-PK (f) Toronto A26/61 (g) Manhattan. 
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PART II: CHARACTERIZATION OF 
IMMUNOFLUORESCENCE, 
PRECIPITATION USING 
THE CANINE ADENOVIRUSES 1 AND 2 BY 
VIRUS NEUTRALIZATION, AND IMMUNO-
MONOCLONAL ANTIBODIES 
This manuscript has been submitted for publication to the Journal of 
Virology. 
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ABSTRACT 
Monoclonal antibodies were produced against the Mirandola strain of 
canine adenovirus type 1 (CAV-1) and the Manhattan strain of canine 
adenovirus type 2 (CAV-2). The monoclonal antibodies were used in an 
indirect fluorescence-antibody (IFA) test and in an vitro virus 
neutralization (VN) assay to examine several strains of each viral type, 
including those used for vaccine production in the United States. Out of 
36 monoclonal antibodies produced against the Mirandola strain, 18 were 
type-specific for CAV-1 by IFA and 13 of those neutralized the virus in 
vitro. The other 18 antibodies bound both CAV-1 and CAV-2 by IFA; 
however, 7 of those specifically neutralized only CAV-1. The 160 
monoclonal antibodies made against the Manhattan strain of CAV-2 yielded 
77 type-specific antibodies by IFA, of which 39 neutralized only CAV-2 in 
vitro. The remaining 83 monoclonal antibodies recognized both CAV-1 and 
CAV-2 by IFA, with 3 of those neutralizing both viral types, and none 
neutralizing only CAV-2. Although type 1 CAV could be readily 
differentiated from type 2 CAV by using monoclonal antibodies in the IFA 
and VN tests, strains within each type could not be differentiated. 
Viral proteins were examined by sodium dodecyl sulfate (SDS)-poly-
acrylamide gel electrophoresis (PAGE) and radioimmune precipitation (RIP) 
with hyperimmune dog serum to each type. Monoclonal antibodies were also 
used in RIP to identify the viral proteins associated with type 
specificity, group specificity, and neutralization. 
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INTRODUCTION 
Two types of canine adenovirus (CAV) have been described. Canine 
adenovirus type 1 (CAV-1) was isolated by Cabasso et al. (1954) from a 
dog with acute hepatitis and was shown to be identical to the infectious 
canine hepatitis virus reported earlier by Rubarth (12, 43). Subse­
quently, Ditchfield et al. (1962) isolated canine adenovirus type 2 
(CAV-2) from throat swabs of a dog with laryngotracheitis (21). In the 
early 1970s, several studies were done to characterize these two viruses 
on the basis of morphology (32), pathogenicity in vivo (3, 8, 19, 21, 50) 
and in vitro (1, 8, 53), and antigenicity (20, 21, 49, 50). Although 
some differences were demonstrated between CAV-1 and CAV-2 in all cases, 
the immunologic distinctness of these two viruses was not documented 
because of the strong cross-reactivity displayed in quantitative 
neutralization tests with animal sera (7, 20, 49, 50). In 1973, Tribe 
and Wolff showed that dogs vaccinated with hexon antigen from 
Toronto A26/61 CAV-2 virus were protected against virulent CAV-1 chal­
lenge (52), and the thrust of research done on these two viruses in the 
late 70s and early 80s centered around their immunologic relatedness in 
that immunity to either pathogen could be induced by vaccination with 
homologous or heterologous CAV types (4, 7, 14, 15, 18, 23). 
Consequently, two strains of CAV-1 (Cornell-1 and Lederle 255) and two 
strains of CAV-2 (Toronto A26/61 and Manhattan) are currently used for 
the production of CAV vaccine in the United States. The identification 
of the immunologic distinctiveness of these 2 viruses, however, has not 
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been pursued. Moreover, although a wealth of Information has been 
published on the characterization of human adenoviruses both at the 
protein (9, 10, 11, 24, 25, 26, 34, 35, 36, 39, 40, 41, 44, 51, 54, 60) 
and DNA (22, 26, 40, 45, 51, 57) levels, the same has not been done for 
the canine adenoviruses. 
My intent in this study, therefore, was twofold. The first was to 
characterize better the proteins of CAV-1 and CAV-2 so that a clearer 
understanding of the biology, immunologic relatedness, and possibly 
immunologic distinctiveness of the CAVs could be developed. The second 
was to identify any differences that might exist among strains of CAV-1 
and CAV-2 so that vaccine strains could be differentiated from field 
strains. 
To accomplish these goals, monoclonal antibodies were produced 
against two virulent strains of CAV, the Mirandola strain of CAV-1 and 
the Manhattan strain of CAV-2. These were then tested by the indirect 
fluorescent-antibody (IFA) technique and by virus neutralization (VN) 
against both the original virus from which each was prepared as well as 
from the heterologous virulent virus. The IFA and VN tests showed 
monoclonal antibodies with type as well as group specificities. Neutral­
ization was associated with both type and group-specific antibodies. 
Sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis (PAGE) 
profiles were performed as well as radioimmune precipitation (RIP) with 
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dog origin CAV-specific antiserum to each [ Sjmethionine-labeled virus 
to identify the major structural polypeptides. Monoclonal antibodies 
were then used in RIP assays to identify which structural polypeptides 
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were precipitated by antibodies that were type-specific, group-specific, 
showed type or group specificity in neutralization, or were group-
specific but showed type-specific neutralization. 
A bank of monoclonal ascites from each fusion were also tested by 
IFA and VN against the Utrecht (prototype), Cornell-1-66, Cornell-l-PK, 
and Lederle 255 strains of CAV-1 and the Toronto A26/61 strain of CAV-2 
in order to identify virus strains useful in differentiating vaccine and 
field virus strains. With the techniques used, however, no detectable 
differences between strains of the same CAV type could be found. 
MATERIALS AND METHODS 
Virus and Cells. Primary dog kidney and Madin and Darby canine 
kidney (MDCK) cells were maintained in Eagle's Minimum Essential Medium 
(MEM) with Earle's salts, 2 mM L-glutamine, 10% heat-inactivated bovine 
fetal serum (BFS), and gentamicin sulfate (50 mg/liter). The Utrecht and 
Lederle 255 strains of CAV-1 and the Toronto A26/61 (Ditchfield) strain 
of CAV-2 were obtained from the American Type Culture Collection, 
passaged one time in primary dog kidney cells, and stored at -60 C. The 
Cornell-1-66 and Cornell-l-PK strains of CAV-1 and the Manhattan strain 
of CAV-2 were a gift from Dr. L. E. Carmichael of Cornell University. As 
received, the Cornell-1-66 strain, a dog isolate (6), was at the third 
passage in primary canine kidney cells; the Cornell-l-PK strain was the 
16th passage of the Cornell-1-66 in primary pig kidney cell cultures; and 
the Manhattan strain was the fifth dog kidney passage. All three of 
these viruses were propagated in primary dog kidney cells and stored at 
-60 C. The Mirandola strain of CAV-1 was from a stock culture kept at 
the National Veterinary Services Laboratories (NVSL). The virus was at 
passage level 31-35 in primary dog kidney cells and stored at -60 C. 
Purified virus samples were prepared by centrifuging tissue culture 
supernatant fluids through 40% sucrose (w/v in 0.2 M phosphate buffer, 
pH 7.5) at 100,000 X g for 1-1/2 hours, then band purifying the pellet in 
a 15-45% discontinuous sucrose gradient. 
Monoclonal Antibody Production. The method used for the production 
of the monoclonal antibodies was the same as previously described by this 
29 
author (55). Briefly, Balb/c mice were inoculated intraperitoneally 
(i.p.) with 0.5 ml of purified virus from either the Mirandola strain of 
CAV-1 or the Manhattan strain of CAV-2. After 2-3 weeks, serum samples 
from the mice were tested by IFA for the presence of antibody to CAV. 
Three days prior to fusion, sero-positive mice were inoculated a second 
time intravenously with 0.2 ml of the same virus. Spleen cells from 
immunized mice were fused with nonsecretor sp2/0 myeloma cells and 
culture fluids from the resulting hybridomas were screened by IFA for the 
presence of antibody. Cloning was carried out in soft agar and the final 
monoclonal antibody products were collected as ascites fluids from 
pristane-primed Balb/c mice that had been injected i.p with selected 
clones. 
IFA Test. MDCK cells were prepared (2 x 10^ cells/ml) in 8-chamber 
tissue culture slides, incubated in an humidified atmosphere of 5% CO^ at 
37 C for 24 hours, inoculated with CAV at a multiplicity of infection 
(MOI) of 0.5 - 0.1, and fixed at 24 hours post-inoculation in acetone. 
Dilutions of 1:10, 1:100, 1:1000, and 1:10,000 of monoclonal ascites 
(50 til) in phosphate-buffered saline were incubated on the cells for 
30 minutes at 37 G in a humidified chamber. One well was used for each 
dilution. Cells were washed in phosphate-buffered saline and stained 
with a 1:150 dilution of fluorescein isothiocyanate (FITC)-labeled goat 
anti-mouse immunoglobulin G (IgG) (heavy and light chain specific) 
antibody (Cappel Laboratories) for 30 minutes. Controls included: 
CAV-inoculated and uninoculated MDCK cells stained by direct FA with 
FITC-labeled dog anti-CAV antiserum; inoculated cells stained by direct 
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FA with the goat anti-mouse conjugate; and uninoculated cells stained by 
IFA with the monoclonal antibodies. 
Virus Neutralization. The ability of the monoclonal antibodies to 
neutralize CAV was assayed by a varying virus-constant antibody test 
carried out in 96-well tissue culture plates. Monoclonal ascites were 
diluted 1:50 or 1:100 in phosphate-buffered saline, mixed with an equal 
volume of virus at each dilution (10 through 10 ), and inoculated 
(50 yl) into each of four wells containing fresh monolayers of MDCK cells 
in MEM supplemented with 10% BFS. Controls included uninoculated cells 
and cells inoculated with virus titrations (25 yl/well) without antibody. 
After 72 hours and at 6 days post-inoculation, cells were read for viral 
cytopathogenic effect (CPE) and titers were calculated by the Reed and 
Muensch 50% endpoint technique (42). A neutralization of 2,2.0 logs of 
virus was considered indicative of specific activity. 
Radiolabeling of Virus, RIP, and Polyacrylamide Gel Electrophoresis. 
CAV-infected and sham-infected MDCK cells were radiolabeled with 
35 [ Sjmethionine and analyzed by radioimmune precipitation (RIP) on a 
sodium dodecyl sulfate (SDS)-10% polyacrylamide gel, in accordance with a 
previously published method (28). MDCK cell monolayers growing in 
2 
150 cm flasks were infected at a high MOI. After 19 hours, the virus 
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and cells were labeled with 10 pCi/ml of [ Sjmethionine in methionine-
deficient medium for 4 hours. Cells were then sonicated, solubilized in 
cold extraction buffer (1% NP-40, 0.1 mM phenylmethylsulfanyl fluoride, 
pH 8.0), and clarified. Either 20 pi of dog anti-CAV serum or 5 ul of 
monoclonal antibody was added to labeled cell lysates and precipitated 
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with protein A-Sepharose CL-4B beads. Samples were dissolved in Laemmli 
buffer (29) containing 2-mercaptoethanol and electrophoresed on SDS-10% 
polyacrylamide gel with either 2.7% or 1.3% N,N'-methylene-bis-acrylamide 
(bis) crosslinker. A monoclonal antibody to pseudorabies virus (PRV) was 
used as a control and molecular size markers were run in the first and 
last lanes of each gel. 
Non-radiolabeled viruses from cell extracts were electrophoresed on 
SDS-PAGE by the Laemmli method and stained with Coomassie Brilliant 
Blue R-250 (29). 
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RESULTS 
Isolation and Characterization of Monoclonal Antibodies to CAV-1 and 
CAV-2 by IFA and VN. Thirty-six monoclonal antibodies against the 
Mirandola strain of CAV-1 and 160 monoclonal antibodies against the 
Manhattan strain of CAV-2 were produced. For screening purposes all 
antibodies were initially tested by IFA against only those two viruses 
and uninoculated MDCK cells. Hybridomas with fluids positive on the 
uninoculated controls were culled as secretors against tissue culture 
antigens. Using CAV-specific antibodies, secreted by different 
hybridomas, various staining patterns for CAV-infected MDCK cells were 
observed. Although nuclear staining was always present, it varied from 
large, lobular inclusions that were usually associated with the nuclear 
membrane, to small, pinpoint inclusions that were diffused throughout the 
nucleus. Some diffuse staining of the cytoplasm was also noted, usually 
in conjunction with all types of nuclear staining except the diffuse, 
pinpoint type. 
After monoclonal ascites were produced, all antibodies were further 
tested by VN against Mirandola and Manhattan. The 1:50 or 1:100 dilution 
of each antibody that was used for VN was determined by its titer as 
calculated from the IFA test. Monoclonal antibodies with IFA titers 
21:1000 were used at 1:100, and those with a lower titer were used at 
1:50. 
Additionally, 20 of the CAV-1 monoclonal antibodies and 34 of the 
CAV-2 monoclonal antibodies were assayed by IFA and VN against the 
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Utrecht, Lederle 255, Cornell-1-66, and Cornell-l-PK strains of CAV-1 and 
the Toronto A26/61 strain of CAV-2. Those virus strains were chosen 
because they were representative of the strains used for vaccine produc­
tion in the United States or because they were a prototype virus 
(Utrecht). Among the strains within each type, either CAV-1 or CAV-2, 
there were no differences detected by either assay. However, between the 
two types, distinctions could be made both in the IFA and VN tests as 
illustrated in Table 1. 
There were 18 different IFA type-specific monoclonal antibodies to 
CAV-1, 13 of which also neutralized the virus, and 77 type-specific 
monoclonal antibodies to CAV-2, 39 of which were neutralizing. Of the 
101 antibodies that bound both viruses in the IFA test, 3 of those also 
neutralized both viruses. Those 3 monoclonal antibodies were from the 
CAV-2 fusion. Also, among the antibodies with specificity for both 
viruses by the IFA technique, there were 7 monoclonal antibodies from the 
CAV-1 fusion that neutralized only CAV-1. 
Characterization of the Structural Proteins of CAV-1 and CAV-2. The 
results of SDS-PAGE analysis of whole virus are shown in Fig. 1. Based 
on the exhaustive characterization that has been done on the human 
adenoviruses (24, 26, 40, 63), tentative assignations were made for the 
viral proteins: hexon (II), penton (III), fiber (IV), fiber-associated 
protein (IVal), hexon-associated proteins (Ilia,VI,VIII), core proteins 
(V,VII), and core-associated protein (IVa2). These are depicted more 
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clearly in Fig. 2-4 in lanes showing RIP of [ S]methionine-labeled 
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CAV with dog CAV-1 and CAV-2 specific antisera. Estimated apparent 
molecular weights (MW) for the major structural polypeptides were 
calculated by plotting the relative rate of migration for the polypeptide 
band against the log of the MW. These data are presented in Table 2, and 
show good correlation with what has been reported for analogous poly­
peptides from human adenoviruses (24, 26, 40, 51, 63). Although most of 
the structural polypeptides were precipitated in the gel in Fig. 2, the 
major antigenic proteins, i.e. hexon (II), penton (III), fiber (IV,IVal), 
and hexon-associated peripentonal protein (Ilia), were not well-resolved. 
In the gels shown in Fig. 3 and 4, therefore, the percent of bis cross-
linker was decreased from 2.7% to 1.3% and electrophoresis was carried 
out for a longer period of time. The resulting gels gave good separation 
of the higher MW components allowing for more detailed examination of 
polypeptides precipitated in the RIPs. 
Both homologous (Fig. 2, lane b; Fig. 3, lane b; Fig. 4, lane c) and 
heterologous (Fig. 2, lane c; Fig. 3, lane c) dog origin CAV type-
specific antisera showed similar RIP bands to both CAV-1 and CAV-2. The 
only dissimilarity noted was in Fig. 3 where there appears to be less 
precipitation of some of the fiber and peripentonal hexon-associated 
polypeptides of CAV-1 by CAV-2 dog antiserum. CAV-1 dog antiserum did 
not precipitate any polypeptides (Fig. 4, lane b) from sham-infected 
MDCK cells (Fig. 4, lane a). 
Representative CAV monoclonal antibodies that had shown different 
specificities in the IFA and VN tests were chosen for use in the RIP. 
Results of those precipitations are shown in Fig. 3 and 4, lanes e-h, and 
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35 
presented In Table 3. In Fig. 3, [ S]methionine-labeled CAV-1 was used 
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as antigen and in Fig. 4, [ S]-CAV-2 was utilized. In lane d of each 
gel, a PRV monoclonal antibody was used as a background control. The RIP 
in lane e of each gel was carried out with type-specific monoclonals (by 
IFA) that did not neutralize. In both cases, the monoclonal antibodies 
bound to an antigenic determinant located on fiber polypeptides. 
Additionally, the CAV-1 specific antibody detected the same antigen on 
hexon-associated peripentonal protein (Ilia). In lane f of each gel, 
where group-specific non-neutralizing monoclonal antibodies were used, 
hexon (II) polypeptide was precipitated in CAV-2 but fiber (IV,IVal) 
proteins were precipitated by CAV-1. The IV polypeptide in Fig. 3, 
lane f, although only faintly visible in the autoradiogram, became more 
evident upon longer exposure. Type-specific, neutralizing monoclonal 
antibodies were utilized in lane g of each gel; for each virus the same 
polypeptides were precipitated with both neutralizing (lanes g) and non-
neutralizing (lanes e) type-specific antibodies. In Fig. 3, lane h, a 
group-specific monoclonal antibody that specifically neutralized CAV-1 
was used. Again, fiber (IV, IVal) and hexon-associated peripentonal 
(Ilia) polypeptides were precipitated. With CAV-2, Fig. 4, lane h, the 
hexon (II) polypeptide was precipitated by a group-specific monoclonal 
antibody that also neutralized both viruses. 
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DISCUSSION 
Since the early 1960s it has been believed that two types of canine 
adenoviruses might exist. However, because quantitative cross-
neutralization studies with CAV-1 and CAV-2 could not, by definition, 
separate these two viruses into distinct adenovirus species (types), 
CAV-1 is still the only provisionally recognized species of CAV (33, 63). 
And yet, studies of the pathology (3, 8, 19, 21, 50), morphology (32), 
and antigenicity (20, 21, 49, 50) of these viruses indicate that there 
are indeed significant differences between the two, similar to the types 
of differences recognized in disparate species of human adenoviruses (48, 
56, 57, 58). 
It has been shown that monoclonal antibodies can be useful tools in 
defining antigenic determinants (17, 30, 37, 46, 59) that can lead to 
typing viruses (38), defining heterogeneity between serotypes and between 
viruses which appear to be related according to neutralization data (5, 
16, 27, 28, 31), and even differentiating between wild and vaccine 
strains (47, 62). In order to validate the possible immunologic 
distinctiveness of the CAVs, therefore, I prepared a bank of monoclonal 
antibodies against the virulent Mirandola and Manhattan strains of CAV-1 
and CAV-2 respectively. These two strains were chosen because they are 
the standard CAV strains used at the NVSL to challenge the efficacy of 
CAV vaccines licensed by the United States Department of Agriculture. I 
hoped that, in addition to validating species distinctness of the CAVs 
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through type-specific monoclonal antibodies, I also could differentiate 
strains and, ultimately, separate vaccine and wild strains. 
Eighteen of 36 monoclonal antibodies produced against CAV-1 and 77 
out of 160 monoclonal antibodies produced against CAV-2 were type-
specific. This indicates the possibility that these two viruses are 
different. In order for the two viruses to be recognized as different 
species, however, several antibodies recognizing a significant number of 
different epitopes must be derived. Epitope mapping of the CAVs using 
neutralizing monoclonal antibodies remains to be done. However, fluores­
cence patterns shown by monoclonal antibodies in the IFA test on MDCK 
cells at the same stage of CAV infection, i.e. 24 hours post-inoculation, 
displayed a wide diversity indicating that a variety of proteins were 
being specifically recognized by antibodies from different hybridomas. 
Although this does not preclude the possibility of shared determinants 
between proteins, it does increase the likelihood that the antibodies are 
binding to different epitopes. 
The CAV-neutralizing monoclonal antibodies produced in this study 
are significant for several reasons. Although monoclonal antibodies have 
been produced against human adenovirus proteins (2, 13), none has been 
reported to have neutralizing capabilities. These CAV antibodies then 
provide a tool for studies on adenovirus neutralization, including 
epitope mapping as well as mechanisms of neutralization. Thirteen CAV-1 
and 39 CAV-2 monoclonal antibodies were type-specific, reinforcing the 
concept of immunologic distinctiveness between these two viruses. 
Moreover, given the fact that 3 out of 83 group-specific CAV-2 antibodies 
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and 7 out of 18 group-specific CAV-1 antibodies were also involved in 
neutralization, one might conclude that neutralization may be closely 
linked to type specificity, but that more than one antigenic site may be 
involved. 
Prior to this study, protein analysis of the structural polypeptides 
of CAV by SDS-PAGE had not been reported. In the characterizations 
reported here, the Mirandola strain of CAV-1 and the Manhattan strain of 
CAV-2 were utilized so that immune precipitations could also be performed 
both with dog CAV strain-specific antisera and the CAV monoclonal anti­
bodies. Structural polypeptides that correlated well with those reported 
for human adenoviruses (26, 40, 63) were noted in both SDS-PAGE of whole 
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virus cell-culture extracts and in RIPs of [ S]methionine-labeled CAV 
with dog strain-specific antisera (Table 2). The only notable difference 
between the two viruses was the lack of detection of the hexon-associated 
peripentonal (Ilia) polypeptide in CAV-2 by CAV-2 dog antiserum (Fig. 4, 
lane c), whereas this same antiserum did precipitate the Ilia polypeptide 
in CAV-1 (Fig. 3, lane c). A possible explanation for this is discussed 
later. 
Much has been written about the immunogenic properties of adeno­
viruses, and models for type and group-specific binding and/or neutral­
ization have been proposed (26, 36, 40, 51). Since a variety of binding 
specificities were noted for the monoclonal antibodies in the IFA and VN 
tests in this study (Table 1), a representative monoclonal from each 
specificity group was selected and tested in RIPs to identify which poly­
peptides would be immunoprecipitated (Table 3). With CAV-1 and CAV-2, 
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both neutralizing and non-neutralizing monoclonal antibodies bound to the 
fiber polypeptides IV and IVal (Fig. 3 and 4, lanes e and g). Addition­
ally, however, the CAV-1 monoclonal antibodies precipitated what appears 
to be the hexon-associated peripentonal Ilia polypeptide. In referring 
back to the RIPs with dog antisera, it was noted that the Ilia 
polypeptide was not precipitated from CAV-2 by CAV-2 dog antiserum. From 
this, one can propose that there are shared antigens on fiber and Ilia 
polypeptide in CAV-1 and at least fiber but possibly also Ilia protein in 
CAV-2 that are distinct and important in type specificity and type-
specific neutralization. The presence of some precipitation of Ilia 
polypeptide from CAV-1 by CAV-2 dog serum (Fig. 3, lane c) supports the 
idea of the shared antigen. Possibly, since the fiber of CAV-2 is longer 
than that of CAV-1, the hexon-associated peripentonal protein of CAV-2 is 
less accessible to the immune system and to antibodies. An RIP with 
CAV-2 antibody and CAV-2 antigen, therefore, would not precipitate Ilia 
polypeptide whereas an RIP with CAV-2 antibody and CAV-1 antigen, with 
shorter fiber and less steric hindrance to antibody binding, would show 
immunoprecipitation of Ilia polypeptide. If Ilia has a shared antigenic 
determinant with another protein such as fiber, the CAV-2 antiserum would 
contain antibody that would bind to Ilia, although probably in a lesser 
quantity than occurs with CAV-1 antiserum (Fig. 3, lane c). 
Group-specific monoclonal antibodies from the CAV-2 fusion, both 
neutralizing and non-neutralizing, immunoprecipitated hexon (II) of CAV-2 
(Fig. 4, lanes f and h). This supports prior evidence for the group 
specificity of hexon antigen which has been documented for adenoviruses 
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of many animal species (13, 36, 57). The interesting point here is that 
type-specific neutralization is associated with fiber protein and 
group-specific neutralization is tied to hexon protein. 
With monoclonal antibodies from the CAV-1 fusion, a different 
pattern emerges. The group-specific antibodies immunoprecipitated the IV 
and IVal polypeptides of fiber instead of hexon (Fig. 3, lanes f and h). 
Moreover, the neutralizing monoclonal antibody also immunoprecipitated 
the Ilia polypeptide of the hexon-associated peripentonal protein. The 
unique feature of this antibody is that it is group-specific in binding 
both viruses in the IFA test, but type-specific in neutralizing only 
CAV-1 in the VN test. The RIP results shown in Fig. 3 suggest that the 
binding of the Ilia protein is important in neutralization of CAV-1. 
Further testing with additional monoclonal antibodies needs to be done to 
substantiate and perhaps further elucidate these ideas. 
It is interesting to note that the group-specific neutralizing 
antibodies from the CAV-2 fusion all neutralize both CAV-1 and CAV-2, but 
that the group-specific neutralizing antibodies from the CAV-1 fusion 
only neutralize CAV-1. Cross-protective immunity studies with the CAVs 
have shown that vaccination with CAV-2 in dogs stimulates a serologic 
response that is completely protective against challenge with either 
virulent CAV-1 or virulent CAV-2 (7, 14, 15, 18). Dog vaccination with 
CAV-1, on the other hand, produces a serologic response that is 
completely protective against challenge with virulent CAV-1 but only 
partially protects against challenge with CAV-2, with challenge virus 
being recovered for a week after exposure (23). Antibodies raised 
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against CAV-1 that bind to the fiber and peripentonal proteins of CAV-1 
and neutralize, possibly by preventing or sterically hindering attachment 
of the virus, might also bind to similar proteins in CAV-2. However, 
since the fiber of CAV-2 is longer, it would still be able to attach to 
cells if antibodies were directed toward an antigenic determinant(s) near 
the base of the fiber leaving the tip free. On the other hand, 
group-specific antibodies directed against hexon attach to both viruses 
in the same physical position facilitating neutralization in the same 
manner for both viruses. This supports the experimental results of Tribe 
and Wolff (52) who protected dogs against CAV-1 challenge by vaccinating 
with CAV-2 hexon. 
Strain differentiation among the CAVs was attempted by testing a 
selected bank of the monoclonal ascites from each fusion against the 
Utrecht, Cornell-1-66, Cornell-l-PK, and Lederle 255 strains of CAV-1 and 
the Toronto A26/61 strain of CAV-2. In the IFA and VN tests, with the 
antibodies used, no differences could be detected between results ob­
served for these viruses and data obtained with Mirandola and Manhattan. 
The possibility of using monoclonal antibodies to differentiate vaccine 
from field strains, therefore, does not seem likely. 
The feasibility of using monoclonal antibodies to differentiate 
CAV-1 from CAV-2 is good. The fact that by random chance approximately 
half of the antibodies from each fusion was type-specific lends credence 
to the idea that there are indeed two species of CAV. This would espe­
cially be true if those antibodies recognized a range of different 
antigens. I have examined the DNA of the CAV strains used in this study 
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by restriction enzyme analysis and have found the genomes of type-1 virus 
strains to be very different from the genomes of type-2 virus strains 
(61). This finding in conjunction with the results from this experiment 
suggest that CAV-1 and CAV-2 should both be recognized as species in the 
genus Mastadenovirus in the family Adenoviridae. 
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TABLE 1. Binding specificities of CAV monoclonal antibodies 
Specificity of 
monoclonal antibodies 
Virus used to produce 
monoclonal antibody 
CAV-1 
a 
CAV-2 
Binds only one 
virus by IFA^ 18/36' 77/160 
Binds only one 
virus by IFA and VN^ 13/36 39/160 
Binds both viruses 
by IFA 18/36 83/160 
Binds both viruses 
by IFA and VN 0/36 3/160 
Binds both viruses 
by IFA but only one 
virus by VN 7/36 0/160 
^Mirandola strain. 
^Manhattan strain. 
'^Indirect fluorescent-antibody technique using fluorescein 
isothiocyanate-labeled goat anti-mouse immunoglobulin G antibody 
(Cappel Laboratories). 
*^Designates number positive out of total number tested. 
^Virus neutralization carried out in vitro. 
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Table 2. Apparent molecular weights of CAV structural polypeptides 
Polypeptide Molecular Weight^ 
Protein Polypeptide CAV-1^ CAV-2^ 
Hexon II 132,000 128,000 
Penton III 92,000 87,000 
Fiber IV 58,000-62,000 58,000-60,000 
Fiber-associated IVal 56,000 57,000 
Hexon-associated III Ilia 65,000 n.k.^ 
(peripentonal) 
Core-associated IVa2 50,000 53,000 
Minor core V 44,000 48,000 
Hexon-associated I VI n.k. 27,000 
Major core VII n.k. 25,000 
Hexon-associated II VIII n.k. 18,700 
Hexon-associaed I IX n.k. 17,500 
(groups of 9) 
^Calculated from radioimmune precipitations with dog origin, CAV 
type-specific antiserum. 
^Mirandola strain. 
Manhattan strain. 
^n.k. = not known. 
Table 3. Structural polypeptides of CAV Immunoprecipitated by monoclonal antibodies in an RIP 
Monoclonal 
antibody 
Virus used 
for fusion 
Specificity 
in IFA* 
Specificity 
in VN 
Polypeptide bound 
in RIP^ 
4A1-C9 CAV-1 CAV-1 neg. fiber (IV, IVal) 
hexon—associated 
peripentonal (Illa) 
4B9-B7 CAV-1 CAV-1 and 
CAV-2 
neg. fiber (IV, IVal) 
2E10-G7 CAV-1 CAV-1 CAV-1 fiber (IV, IVal) 
hexon-associated 
peripentonal (Ilia) 
2G5-G4 CAV-1 CAV-1 and 
CAV-2 
CAV-1 fiber (IV, IVal) 
hexon-as s ociated 
peripentonal (Ilia) 
3G4-B10 CAV-2 CAV-2 neg. fiber (IV, IVal) 
5D6-B11 CAV-2 CAV-1 and 
CAV-2 
neg. hexon (II) 
3B5-D9-F12 CAV-2 CAV-2 CAV-2 fiber (IV, IVal) 
1C12-G8 CAV-2 CAV-1 and 
CAV-2 
CAV-1 and 
CAV-2 
hexon (II) 
^IFA = Indirect fluorescent antibody technique. 
^VN = Virus neutralization in vitro. 
^RIP = Radioimmune precipitation. 
Fig. 1. SDS-PAGE of CAV structural polypeptides. Tissue culture fluids 
from CAV-infected and sham-inoculated MDCK cells were clarified 
by low speed centrifugation, pelleted through 40% sucrose, 
electrophoresed on an SDS-10% polyacrylamide gel, with 2.7% 
bis, under reducing conditions, and stained with Coomassie 
Brilliant Blue R-250. Lane a. MM markers. Lane b. Control 
sham-inoculated cell lysate. Lane c. CAV-1, Mirandola strain. 
Lane d. CAV-2, Manhattan strain. Proteins identified include; 
hexon (II), penton (III), hexon-associated III peripentonal 
(Ilia), fiber (IV), fiber-associated (IVal), core-
associated (IVa2), minor core (V), hexon-associated I (VI), 
major core (VII), hexon-associated II (VIII). MW markers are 
identified. 
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Fig. 2. RIP of [ S]methionine-labeled CAV-2 structural polypeptides. 
CAV-2-infacted (Manhattan strain) MDCK cells were labeled with 
35 
10 yCi/ml of [ Sjmethionine for 4 hours, detergent disrupted, 
and sonicated. Proteins were immunoprecipitated with 20 yl of 
CAV-1 or CAV-2 dog antiserum and protein A-Sepharose CL-4B 
beads. The immunoprecipitates were electrophoresed on an 
SDS-10% polyacrylamide gel, with 2.7% bis, under reducing 
conditions. Lane a. CAV-2-infected cell lysate. Lane b. RIP 
of CAV-2 by dog anti-CAV-2-Manhattan antiserum. Lane c. RIP 
of CAV-2 by dog anti-CAV-l-Mirandola antiserum. Proteins 
identified include: hexon (II), penton (III), hexon-associated 
III peripentonal (Illa), fiber (IV), fiber-associated (IVal), 
core-associated (IVa2), minor core (V), hexon-associated I 
(VI,IX), major core (VII), hexon-associated II (VIII). MW 
markers were identified from standards electrophoresed in this 
gel. 
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Fig. 3. RIP of [ S]methionine-labeled CAV-1 structural polypeptides. 
CAV-l-infected (Mirandola strain) MDCK cells were labeled with 
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10 yCi/ml of [ S]methionine for 4 hours, detergent disrupted, 
and sonicated. Proteins were immunoprecipitated with either 
20 yl of CAV-1 or CAV-2 dog antiserum or 5 yl of monoclonal 
antibody ascites and protein A-Sepharose CL-4B beads. The 
immunoprecipitates were electrophoresed on an SDS-10% 
polyacrylamide gel, with 1.3% bis, under reducing conditions. 
Lane a. CAV-l-infected cell lysate. Lane b. RIP of CAV-1 by 
dog anti-CAV-l-Mirandcla antiserum. Lane c. RIP of CAV-1 by 
dog anti-CAV-2-Manhattan antiserum. Lane d. Control RIP of 
CAV-1 by PRV monoclonal antibody. RIP of CAV-1 by monoclonal 
antibodies 4A1-C9 (lane e), 4B9-B7 (lane f), 2E10-G7 (lane g), 
2G5-G4 (lane h). Proteins identified include: hexon (II), 
penton (III), hexon-associated peripentonal (Ilia), fiber (IV), 
fiber-associated (IVal), core-associated (IVa2), minor 
core (V). MW markers were identified from standards electro­
phoresed in this gel. 
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Fig. 4. RIP of [ Sjmethionine-labeled CAV-2 structural polypeptides. 
CAV-2-infected (Manhattan strain) or sham-inoculated MDCK cells 
35 
were labeled with 10 yCi/ml of [ S]methionine for 4 hours, 
detergent disrupted, and sonicated. Proteins were 
immunoprecipitated with either 20 jil of CAV-1 or CAV-2 dog 
antiserum or 5 nl of monoclonal antibody ascites and protein 
A-Sepharose CL-4B beads « The immunoprecipitates were 
electrophoresed on an SDS-10% polyacrylamide gel, with 1.3% 
bis, under reducing conditions. Lane a. Sham-Inoculated 
control cell lysate. Lane b. RIP of control cell lysate by 
dog anti-CAV-l-Mirandola antiserum. Lane c. CAV-2-infected 
cell lysate. Lane d. Control RIP by PRV monoclonal antibody. 
RIP of CAV-2 by monoclonal antibodies 3G4-B10 (lane e), 5D6-B11 
(lane f), 3B5-D9-F12 (lane g), 1C12-G8 (lane h). Proteins 
identified include: hexon (II), penton (III), hexon-associated 
peripentonal (Ilia), fiber (IV), fiber-associated (IVal), 
core-associated (IVa2), minor core (V). MW markers were 
identified from standards electrophoresed in this gel. 
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SUMMARY AND DISCUSSION 
Monoclonal antibodies against the Mirandola strain of canine adeno­
virus type 1 (CAV-1) and the Manhattan strain of canine adenovirus type 2 
(CAV-2) were prepared as previously described by this author (30), and 
utilized in tests for indirect fluorescent-antibody (IFA), virus neutral­
ization (VN), and radioimmunoprecipitation (RIP) to establish antigenic 
differences between CAV-1 and CAV-2. Type-specific monoclonal anti­
bodies, both neutralizing and non-neutralizing, were further tested 
against the Utrecht (prototype), Cornell-1-66, Cornell-1-PK, and 
Lederle 255 strains of CAV-1 and the Toronto A26/61 (Ditchfield) strain 
of CAV-2 by IFA and VN. Using these techniques and antibodies, no strain 
differences were observed within a species. However, in all cases, CAV-1 
could be readily differentiated from CAV-2. Moreover, since these viral 
strains include all that are used for vaccine production in the United 
States, the goal of developing an in vitro assay for the identification 
of CAV-1 vs CAV-2 has been fulfilled. 
Structural polypeptides for both viruses were determined, and these 
data correlate with what has been published for human adenovirus struc­
tural proteins (15, 17, 23, 34). 
The RIPs with dog anti-CAV sera revealed that, with such polyclonal 
sera, CAV-1 and CAV-2 are antigenically very similar. The monoclonal 
antibodies utilized in RIP, however, indicated that although fiber 
protein is important for type specificity for both CAV-1 and CAV-2, group 
specificity is linked to hexon protein with CAV-2 and fiber protein with 
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CAV-1. Additionally, there appears to be more that 1 protein (and 
probably more than 1 mechanism) involved in neutralization. Much has 
been written on the immunogenic properties of adenoviruses, and models 
for type and group-specific binding and/or neutralization have been 
proposed (17, 21, 23, 28). Data presented in this dissertation should 
help confirm some of these ideas. 
In an attempt to differentiate strains, and, to verify that CAV-1 
and CAV-2 are distinct types of CAV, restriction enzyme analyses on the 
DNA of the Utrecht, Lederle 255, Cornell-1-66 and Cornell-l-PK strains of 
CAV-1 and on the Toronto A26/61 (Ditchfield) and Manhattan strains of 
CAV-2 were performed. From this, genome size for the CAVs was estimated 
at 20 to 21 X 10^ daltons. As with the human adenoviruses (20, 31, 32, 
33) and the human, bovine, porcine and equine herpesviruses (5, 6, 14, 
16, 22, 25), where restriction enzyme analysis detects type and/or strain 
differences when they exist, analysis of the CAVs showed that CAV-1 is 
genomically different than CAV-2. Moreover, some strain distinctions 
could be made. This aspect of the study, in addition to providing 
another in vitro method for distinguishing CAV-1 from CAV-2, provided a 
means for possible strain identification and further proof of the 
separate species characteristics of CAV-1 and CAV-2. 
This investigation is certainly not exhaustive. Although techniques 
for the differentiation and characterization of the CAVs have been 
described and information has been gained, much remains to be done. The 
availability of a bank of monoclonal antibodies will make possible such 
studies as epitope mapping, RIPs, pathological examinations using 
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monoclonal antibodies as probes, in vitro and in vivo examinations of the 
mechanisms of neutralization, and cloning. Perhaps additional analysis 
with different restriction enzymes will provide further information on 
strain differentiation. The observation that genome alteration can occur 
with viral attenuation by passage through heterologous cell culture 
merits further examination. The CAV strains used in this study were 
parent stocks for the currently marketed vaccines. If the vaccine 
viruses were extensively passaged in culture or passaged in heterologous 
culture to establish a master seed from which vaccine is now produced, 
then restriction enzyme analysis of those vaccines might provide useful 
information on both strain identity and any genomic changes that may have 
occurred. 
The principal accomplishments of this investigation are the 
following: 1) the development of i^ vitro methods for distinguishing 
CAV-1 from CAV-2 through the use of monoclonal antibodies and restriction 
enzyme analysis; 2) the discovery of a possible method of strain 
differentiation of CAVs by restriction enzyme analysis; 3) the 
characterization by SDS-PAGE and RIP of CAV-1 and CAV-2 structural 
polypeptides; 4) the investigation of CAV proteins important in 
type-specific, group-specific, and neutralization binding; 5) the 
validation of the species distinctiveness of CAV-1 and CAV-2. 
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